Surgical treatment and adjuvant chemotherapy in borderline ovarian tumors

Öz

Borderline ovarian tumors are generally seen in reproductive ages. While the tumor does not have an invasive nature to ovarian tissue, it may have some features in the peritoneal cavity that could predict the prognosis. The surgical treatment and adjuvant chemotheraphy for borderline ovarian tumors are in debate. However in this situation knowing the literature and modifying the results of researches on each patient may draw the clinical approach on these tumors.

Anahtar Kelimeler

• Borderline ovarian tumor,chemotherapy,fertility

Borderline over tümörlerinde cerrahi ve adjuvan kemoterapi

Öz

Borderline over tümörleri genellikle reprodüktif yaşlarda görülmektedir. Tümör overyan dokuya invaziv bir yapıya sahip olmamakla beraber, peritoneal kavitede prognozu tayin edecek yapılar içerebilir. Borderline over tümörleri için cerrahi tedavi ve adjuvan kemoterapi tartışmalı kavramlardır. Yine de bu durumda literatürü bilmek ve yapılan çalışmaların sonuçlarını her bir hasta için modifiye etmek bu tümörlere klinik yaklaşımın planlanmasını sağlayacaktır.

Anahtar Kelimeler

• Borderline over tümörü,kemoterapi,fertilite

Kaynakça

1. Du Bois A, Ewald-Riegler N, du Bois O, Harter P. : Borderline tu- mors of the ovary: A systematic review. Geburtsh Frauenheilk 2009;69:807-833.
2. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C: Be- havior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Cnc. 2001; 19:2658-2664.
3. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Nam JH: Micro- papillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 2011;123:511-516.
4. Ayhan A, Guvendag Guven ES, Guven S, Kucukali T: Recurrence and prognostic factors in borderline ovarian tumors. Gynecol Oncol 2005;98:439-445.
5. Ayhan A, Guven S, Guven ES, Kucukali T: Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gy- necol Scand 2007;86:484-490.
6. Gungor T, Kaba M, Baser E, Yalcin H, Bayramoglu H, Besli M: Ad- vanced stage micropapillary serous borderline ovarian tumor in a postmenopausal woman: a case report. J. Turk German Gynecol Assoc. 2012;13:208-211.
7. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Ma- lign mural nodules associated with serous ovarian tumor of border- line malignancy: a case report and literature review. Arch.Gynecol Obstet 2010;281:485-490.
8. Fischerova D, Zikan M, Dundr P, Cibula D: Diagnosis, treat- ment, and follow-up of borderline ovarian tumors. The Oncologist 2012;17:1515-1533.

9. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrick- son MR: Ovarian serous tumors of low malignant potential (border- line tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am. J Surg Pathol 2005;29:707-723.
10. Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P et al. Prognostic factors for patients with advanced stage serous borderli- ne tumours of the ovary. Ann of Oncol 2003;14:592-598.
11. Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C: Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998;83:2157-2163.
12. Wu TI, Lee CL, Wu MY, Hsueh S, Huang KG, Yeh CJ, Lai CH: Prog- nostic factors predicting recurrence in borderline ovarian tumors. Gynecol Oncol 2009;114:237-241.
13. Alagkiozidis I, Dorcelus S, Somma J, Chun LY, Salame G: Invasive recurrence of serous borderline ovarian tumor as multifocal lymp- hadenopathy 25 years after initial diagnosis. Gynecol Oncol. Case Rep. 2012;2:136-138.
14. Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E: Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet oncology 2012;13:e103-115.
15. Lhomme C, Ray-Coquard I, Guastalla JP, Bataillard A, Thomas L, Bonnier P, Dargent D, Dohollou N. et al.: [Clinical practice guideli- nes: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]. Bulletin du cancer 2004;91:609-620.
16. Morice P: Borderline tumours of the ovary and fertility. Eur. J. Can. 2006;42:149-158.
17. Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML: Bor- derline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med. 2003;48:756-760.
18. Song T, Choi CH, Park HS, Kim MK, Lee YY, Kim TJ, Lee JW, Bae DS et al: Fertility-sparing surgery for borderline ovarian tumors: on- cologic safety and reproductive outcomes. IJGC 2011;21:640-646.
19. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Surgical ma- nagement of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol 2009;113:75-82
20. Tsai HW, Ko CC, Yeh CC, Chen YJ, Twu NF, Chao KC, Yen MS: Unilateral salpingo-oophorectomy as fertility-sparing surgery for bor- derline ovarian tumors. J Chin Med Acssoc 2011;74:250-254.
21. Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, Goksedef BP, Sakarya DK et al: Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic On- cology Group study. Gynecol Oncol 2013;131:546-550.
22. Kanat-Pektas M, Ozat M, Gungor T, Sahin I, Yalcin H, Ozdal B: Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors? Arch Gynecol 2011;283:879- 884.
23. Lesieur B, Kane A, Duvillard P, Gouy S, Pautier P, Lhomme C, Mori- ce P, Uzan C: Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011;204:431-437.
24. McKenney JK, Balzer BL, Longacre TA: Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tu- mors): pathology, prognosis, and proposed classification. Am J Surg Pathol 2006; 30:614-624.
25. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR et al.: Risk factors for recurrence of ovarian border- line tumors. Gynecol Oncol 2011;120:480-484.
26. Benito V, Lubrano A, Arencibia O, Medina N, Alvarez Eva E, Andujar M, Falcon Juan M, Falcon O: Serous and mucinous borderline ova- rian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 2010;153:188-192.
27. Koskas M, Uzan C, Gouy S, Pautier P, Lhomme C, Haie-Meder C, Duvillard P, Morice P: Prognostic factors of a large retrospective se- ries of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2011;18:40-48.
28. Trope C, Davidson B, Paulsen T, Abeler VM, Kaern J: Diagnosis and treatment of borderline ovarian neoplasms “the state of the art”. Eur J Gynecol Oncol 2009;30:471-482.
29. Darai E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P: Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Rep- rod Upd. 2013; 19:151-166.
30. Swanton A, Bankhead CR, Kehoe S: Pregnancy rates after conser- vative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol 2007; 135:3-7.
31. Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bag- noli A: Fertility and tumor recurrence rate after conservative lapa- roscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001; 76:999-1004.
32. Nam JH: Borderline ovarian tumors and fertility. Cur Opinion Obstet Gynecol 2010; 22:227-234.
33. Sallum LF, Sarian LO, Lucci De Angelo Andrade L, Vassallo J, Soares FA, Pinto GA, Ferreira PA, Derchain S: Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status. J Gynecol Oncol 2013; 24:167-176.
34. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E: Laparosco- pic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005; 16:403-410.
35. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T: Manage- ment of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol 2006; 101:255-260.
36. J-H Kim, J-Y Park, D-Y Kim, Y-M Kim, Y-T Kim, J-H Nam: Compari- son of Laparoscopic and Laparotomic Surgery for Borderline Ovari- an Tumor. J Min Inv Gynecol 2009;16:41.
37. Maneo A, Vignali M, Chiari S, Colombo A, Mangioni C, Landoni F: Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94:387-392
38. Odegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M: Surgery of borderline tumors of the ovary: retrospective comparison of short- term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand. 2007; 86:620-626.
39. Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO: Interven- tions for the treatment of borderline ovarian tumours. The Cochrane database of syst rev 2010; CD007696.
40. Leary A, Petrella MC, Pautier P, Duvillard P, Uzan C, Tazi Y, Ledoux F, Gouy S et al.: Adjuvant platinum-based chemotherapy for border- line serous ovarian tumors with invasive implants. Gynecol Oncol 2014; 132:23-27.
41. Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C: Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998; 82:1096-1103.